Figure 9

(A) Representative TAF spatial distribution profiles (positive mode, m/z 477 → 270, 346) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants; D0 indicates tissues from an unmedicated control; D3, D7, D14, D21, and D28 indicate tissue specimens collected with the TAF implant in place at study days 3, 7, 14, 21, and 28, respectively. The first row represents mass spectrometry images, generated at a spatial resolution of 50 µm and the color key in the legend indicates relative abundance, with red representing the highest signal intensity (100%) and blue representing the lowest signal (0%) for the measured ion; all images were scaled individually. The second row represents an overlay of the IMS signals and light microscopy images of the tissue specimens. The third row corresponds to H&E serial section stains of matching tissue specimens. Scale bar, 1 mm. (B). Representative Metabolite X spatial distribution profiles (positive mode, m/z 359 → 270, 288) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants. Additional details are the same as in (A). (C). Representative Metabolite Y spatial distribution profiles (positive mode, m/z 401 → 270) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants Additional details are the same as in (A). (D). Representative TFV spatial distribution profiles (negative mode, m/z 286 → 134, 151) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants. Additional details are the same as in (A). (E). Representative TFV-MP spatial distribution profiles (negative mode, m/z 366 → 268, 348) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants. Additional details are the same as in (A). (F). Representative TFV-DP spatial distribution profiles (negative mode, m/z 446 → 159, 348) in mouse dermal tissue sections adjacent to high-releasing (0.58 mg d^-1) TAF implants. Additional details are the same as in (A).